Davita Inc Stock Price, News & Analysis

On September 13, 2022, DaVita Inc. announced the appointment of Adam H. Schechter as an independent director to its Board, effective September 20, 2022. Schechter, currently CEO of Labcorp, has over 30 years of experience in healthcare, previously holding leadership roles at Merck & Co.. His extensive experience in the healthcare ecosystem aims to enhance DaVita's mission of improved patient care. Mr. Schechter will also serve on the Audit and Compliance & Quality Committees. DaVita is a leading kidney care provider, serving 198,000 patients at 2,810 centers in the U.S.

Federman & Sherwood has launched an investigation into DaVita, Inc. (NYSE: DVA) due to a significant data breach confirmed on September 8, 2022. The breach involved unauthorized access to sensitive consumer data, affecting individuals' names, addresses, Social Security numbers, medical, and health insurance information. DaVita operates approximately 2,816 outpatient dialysis centers across the United States, raising concerns over consumer data protection and potential legal implications from the breach.

DaVita Inc. reported its financial results for Q2 2022, highlighting consolidated revenues of $2.927 billion and a net income of $225 million.

Operating income reached $433 million, with diluted EPS at $2.30. Despite challenges like a global pandemic and supply chain issues, performance showed resilience with 7,269,160 total dialysis treatments conducted.

The company repurchased 3.9 million shares at an average cost of $95.56 per share, reflecting a commitment to shareholder value.

The American Diabetes Association (ADA) and DaVita announced the launch of a digital platform aimed at combating diabetes-related kidney complications on July 25, 2022. This initiative targets the one in seven U.S. adults affected by diabetes, which is the leading cause of chronic kidney disease (CKD). The platform offers resources including Kidney Smart classes, meal planning, and physician engagement tips to empower diabetes patients. Dr. Robert Gabbay of ADA emphasized the importance of understanding the diabetes-kidney connection to improve health outcomes.

DaVita Inc. (NYSE: DVA) announced its quarterly conference call to discuss second quarter results on August 1, 2022, at 5:00 p.m. ET. Results will be released after market close the same day. Investors can access the call via dial-in at 877-918-6630 or through a webcast at the DaVita IR website. As of March 31, 2022, DaVita served 200,800 patients across 2,809 outpatient dialysis centers in the U.S. and 346 centers in other countries, focusing on improving kidney care quality.

Rockwell Medical (RMTI) has successfully closed a $7.5 million second tranche investment from DaVita (DVA), bringing the total capital raised this quarter to $30 million. This funding will extend Rockwell's cash runway to advance its Ferric Pyrophosphate Citrate (FPC) development programs and improve their dialysis business. They are preparing for a Phase 2 clinical trial of FPC in home infusion patients, pending FDA clearance, which will require a microbial challenge study to ensure patient safety.

DaVita Inc. (NYSE: DVA) announced a special investor conference call scheduled for June 23, 2022, at 8:45 a.m. EDT. The call follows a U.S. Supreme Court ruling concerning the Medicare Secondary Payor Act. Investors can join the call via a designated phone number or listen to a webcast. DaVita is focused on enhancing kidney care, having served 200,800 patients at 2,809 outpatient dialysis centers in the U.S. as of March 31, 2022. The company aims to improve patient outcomes and accessibility in kidney health.

Medtronic and DaVita are launching a new independent company focused on kidney care technology to enhance treatment experiences and patient outcomes. This collaboration aims to leverage Medtronic's healthcare technology skills and DaVita's expertise in kidney care to develop innovative products, including home-based dialysis solutions. Each company will hold equal stakes in the new entity, which will be governed by an independent management team. The transaction is expected to close within a year, pending regulatory approvals.

Medtronic and DaVita have announced a partnership to create a new independent kidney care-focused medical device company, NewCo. This joint venture aims to enhance kidney treatment and patient outcomes by leveraging Medtronic's healthcare technology and DaVita's expertise in kidney care. NewCo will develop innovative therapies and products, especially for home-based dialysis treatments, serving over three million kidney failure patients globally. Each company will have equal ownership and contribute financially to support NewCo's initial operations.